Cndanting Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable. Plantar warts are specifically located on the soles of the feet, are tender to touch, and exhibit an interrupted footprint pattern.

Limitations of Use: There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes, after which the area must be dried completely.

A sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. It is essential to allow the application to dry fully.

This procedure may be repeated once or twice daily as necessary, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application is not recommended on irritated skin or any area that is infected or reddened, as this may exacerbate the condition. The product should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes due to the potential for adverse reactions. Additionally, individuals with diabetes or poor blood circulation should avoid use, as these conditions may increase the risk of complications.

Contact with the eyes must be avoided; in the event of exposure, the eyes should be flushed with water for 15 minutes.

Warnings and Precautions

For external use only; it is imperative to keep the product away from fire and flame to prevent any potential hazards.

In the event of accidental ingestion, immediate medical assistance is required. Healthcare professionals should advise patients to contact the Poison Control Center at 1-800-222-1222 without delay.

Should any discomfort persist during the use of this product, it is essential for patients to discontinue use and consult a healthcare provider for further evaluation and guidance.

Side Effects

Patients should be aware that the product is for external use only and should be kept away from fire and flame to prevent any potential hazards.

In the event that discomfort persists, it is advised that patients stop using the product and consult a healthcare professional. This recommendation is crucial to ensure safety and address any underlying issues that may arise during use.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Cndanting Wart Remover (salicylic acid 17% wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The safety of this product during pregnancy has not been established, as the prescribing information does not provide specific data regarding its use in pregnant patients. There are no known safety concerns, dosage modifications, or special precautions outlined for women who are pregnant or may become pregnant. Healthcare professionals should weigh the potential benefits against any unknown risks when considering this product for use in pregnant patients. It is advisable to monitor for any adverse effects and to counsel patients on the lack of available data regarding the use of this product during pregnancy.

Lactation

There is no specific information available regarding the use of this product in lactating mothers. Additionally, there is no data concerning the potential for excretion of the product in breast milk or its effects on breastfed infants. Healthcare professionals should consider the lack of information when advising lactating mothers on the use of this product.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary significantly depending on the substance involved and the individual patient’s characteristics. Symptoms may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, including airway management, oxygen supplementation, and intravenous fluids.

If the specific agent involved in the overdose is known, appropriate antidotes or specific treatments should be administered as indicated. Continuous monitoring of the patient’s condition is crucial, and healthcare providers should be prepared to manage complications that may arise during the course of treatment.

In all cases of suspected overdosage, consultation with a poison control center or a medical toxicologist is advised to ensure optimal management and to obtain guidance on further therapeutic interventions.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important to instruct patients not to apply the product on irritated skin or on any areas that are infected or reddened. Additionally, patients should be cautioned against using the product on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Those with diabetes or poor blood circulation should also refrain from using the product.

Patients should be informed to discontinue use and consult a doctor if discomfort persists after application. It is crucial to emphasize the importance of avoiding contact with the eyes; if the product accidentally enters the eye, patients should flush the eye with water for 15 minutes. Patients should be reminded that the product is non-edible and should be stored with the cap tightly closed at room temperature, away from heat sources.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It should be stored at room temperature, ensuring that the temperature does not exceed 37°C (99°F) to avoid excessive heat exposure. Proper storage conditions are essential to maintain the integrity of the product.

Additional Clinical Information

The medication is administered topically, with the recommended frequency being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Cndanting Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)